A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2.

Autor:	Costa Rocha VP; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, FIOCRUZ, Salvador, Bahia, Brazil., Souza Machado BA; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil.; University Center SENAI CIMATEC, Salvador, Bahia, Brazil., Barreto BC; Gonçalo Moniz Institute, FIOCRUZ, Salvador, Bahia, Brazil., Quadros HC; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, FIOCRUZ, Salvador, Bahia, Brazil., Santana Fernandes AM; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil., Lima EDS; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil., Bandeira ME; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil., Meira CS; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, FIOCRUZ, Salvador, Bahia, Brazil., Moraes Dos Santos Fonseca L; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil., Erasmus J; HDT Biocorp, EUA, Seattle, WA, USA., Khandhar A; HDT Biocorp, EUA, Seattle, WA, USA., Berglund P; HDT Biocorp, EUA, Seattle, WA, USA., Reed S; HDT Biocorp, EUA, Seattle, WA, USA., José da Silva Badaró R; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil., Pereira Soares MB; SENAI Institute of Innovation (ISI) in Health Advanced Systems (CIMATEC ISI SAS), SENAI CIMATEC, Salvador, Bahia, Brazil.; Gonçalo Moniz Institute, FIOCRUZ, Salvador, Bahia, Brazil.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2024 Feb 06; Vol. 10 (4), pp. e25539. Date of Electronic Publication: 2024 Feb 06 (Print Publication: 2024).
DOI:	10.1016/j.heliyon.2024.e25539
Abstrakt:	Immune imprinting is now evident in COVID-19 vaccinated people. This phenomenon may impair the development of effective neutralizing antibodies against variants of concern (VoCs), mainly Omicron and its subvariants. Consequently, the boost doses with bivalent vaccines have not shown a significant gain of function regarding the neutralization of Omicron. The approach to design COVID-19 vaccines must be revised to improve the effectiveness against VoCs. Here, we took advantage of the self-amplifying characteristic of RepRNA and developed a polyvalent formulation composed of mRNA from five VoCs. LION/RepRNA Polyvalent induced neutralizing antibodies in mice previously immunized with LION/RepRNA D614G and reduced the imprinted phenotype associated with low neutralization capacity of Omicron B.1.1.529 pseudoviruses. The polyvalent vaccine can be a strategy to handle the low neutralization of Omicron VoC, despite booster doses with either monovalent or bivalent vaccines. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.V.P.C.R.; B.A.S.M.; B.C.B; H.C.Q.; A.M.S.F.; E.S.L.; M.E.B.; C.S.M.; L.M.S.F., R.J.S.B.; and M.B.P.S. declare no conflict of interest. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu